5th Floor, Brigade Towers,
Financial District, Gachibowli,
Hyderabad - 500032,
The Parkinson’s Disease Drugs Market is Segmented by Mechanism of Action (Dopamine Agonists, Anticholinergic, MAO-B Inhibitors, Amantadine, Carbidopa-levodopa, COMT Inhibitors, and Other Mechanisms of Action), and Geography.
Fastest Growing Market:
Parkinson's disease is a chronic disorder that gradually leads to progressive deterioration of motor functions, caused by the loss of dopamine-producing brain cells. The Parkinson’s disease drugs market is expected to witness significant growth, owing to the increasing cases of Parkinson’s disease, with the growth in the aging population, which may drastically result in increasing the market size during the forecast period. Pharmaceutical firms are developing new and improved therapies for Parkinson's disease (PD). Recently, there have been some major product launches in Parkinson's disease therapeutics and other assistive therapeutics. For instance, Adamas Pharmaceuticals’ amantadine extended-release capsules, Gocovri, were launched in January 2018. Gocovri was the first drug indicated for dyskinesia developed due to the long-term use of levodopa. Furthermore, most of the global firms have a robust drug pipeline for the treatment of Parkinson's disease. As per the estimates, many blockbuster drugs are expected to be launched during the forecast period, which may boost the overall market growth.
The Parkinson’s disease drugs market report has been segmented by mechanism of action and geography. By mechanism of action, the market studied is segmented into dopamine agonists, anticholinergic, MAO-B inhibitors, amantadine, carbidopa-levodopa, COMT inhibitors, and other mechanisms of action.
|By Mechanism of Action|
|Other Mechanisms of Action|
Report scope can be customized per your requirements. Click here.
Carbidopa-levodopa therapy is the most effective medication for alleviating the motor symptoms of PD. However, it has been observed that this medication is not as effective as intended. Therefore, it is imperative that co-therapeutic agents, such as COMT (catechol-O-methyltransferase) inhibitors, are used along with carbidopa-levodopa therapy. The two most common COMT inhibitors used in the treatment of Parkinson’s disease are Comtan (entacapone) and Tasmar (tolcapone). Both these medications are available in the form of tablets, and they are routinely prescribed in conjunction with carbidopa-levodopa therapy. Furthermore, due to the rapidly aging population, the prevalence of Parkinson’s disease is also expected to grow, which may drive the demand for these drugs.
To understand key trends, Download Sample Report
According to the National Institute of Health, approximately 1.2 million people in the United States are projected to have Parkinson’s disease by 2030. It is the second-most common neurodegenerative disorder in the United States. In addition, there are thousands of patients who go undetected. As the aging population levels continue to grow, the number of people suffering from Parkinson's disease (PD) may also continue to grow, which is expected to double by 2040. The number of patients suffering from Parkinson’s disease, combined with the availability of reimbursements and high awareness, is boosting the growth of the market. Furthermore, the high cost of Parkinson's disease therapeutics in the United States leads to significant market size in terms of revenue. The average cost of Parkinson’s medication is approximately USD 2,500 per year, and Parkinson’s-related surgery can cost up to USD 100,000 per patient.
To understand geography trends, Download Sample Report.
The Parkinson's disease drugs market is becoming highly competitive. The recent product launches and the high number of therapeutics in product pipelines of the global pharmaceutical firms are contributing to the dynamic nature of the market. Several new products are expected to be launched during the forecast period, which may lead to significant changes in the market shares of pharmaceutical firms that are currently active in the market.
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Geriatric Population and Burden of Parkinson's Disease
4.2.2 Growing Awareness Among the Population
4.2.3 Recent Drug Approvals
4.3 Market Restraints
4.3.1 Generic Competition to Key Therapies
4.3.2 High Cost of Treatment
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Mechanism of Action
5.1.1 Dopamine Agonists
5.1.3 MAO-B inhibitors
5.1.6 COMT Inhibitors
5.1.7 Other Mechanisms of Action
5.2.1 North America
126.96.36.199 United States
188.8.131.52 United Kingdom
184.108.40.206 Rest of Europe
220.127.116.11 South Korea
18.104.22.168 Rest of Asia-Pacific
5.2.4 Middle-East and Africa
22.214.171.124 South Africa
126.96.36.199 Rest of Middle-East and Africa
5.2.5 South America
188.8.131.52 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Merck & Co. Inc.
6.1.2 Impax Laboratories Inc.
6.1.3 AbbVie Inc.
6.1.4 Mylan NV
6.1.5 Boehringer Ingelheim GmbH
6.1.6 GlaxoSmithKline PLC
6.1.7 M Somerset Pharmaceuticals Inc.
6.1.8 Teva Pharmaceuticals Industries Ltd
6.1.9 Pfizer Inc.
6.1.10 Novartis International AG
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
**Competitive Landscape Covers - Business Overview, Financials, Products and Strategies, and Recent Developments